Metabolic Signaling Research

Retatrutide — 5 mg

Name: Retatrutide — 5 mg
Brand: Vectrum Peptides
Price: 40.0 EUR
Availability: InStock

5 mg / vial

Retatrutide is an investigational peptide that activates GLP-1, GIP and glucagon receptors. These hormone systems affect hunger, digestion, insulin, blood sugar and energy use. Human trial results apply to the specific investigational drug, not this 5 mg laboratory vial.

€40,00

Research only Secure checkout

For in-vitro laboratory research only. Not for human or veterinary use.This information is provided for scientific and educational product context only. It does not describe or recommend human use, veterinary use, diagnosis, treatment, prevention, dosage, administration, or clinical application.

Weight Loss

Human studies found large average reductions in body weight. Most of the weight lost came from body fat, although results differed between people.

Less Hunger

It affects hunger and fullness signals. People may feel less hungry, become full sooner and find it easier to eat less.

Blood Sugar and Insulin

It helps the body release insulin when blood sugar rises. This can improve how the body handles sugar after eating.

Body Fat and Liver Fat

Research found reductions in stored body fat and fat inside the liver. The liver helps process and store energy.

Energy Use

It affects hormone signals involved in how the body uses food and stored energy.

Retatrutide remains investigational, and results differ between people.

Full research details

Full research details for Retatrutide — 5 mg

Read the supporting laboratory, animal and human research. This section does not provide instructions for human or veterinary use, diagnosis, treatment, prevention, dosage or administration.

What this compound is

This 5 mg listing contains retatrutide, an investigational peptide designed to activate three hormone receptors: GLP-1, GIP and glucagon receptors. These receptors help the body coordinate digestion, blood sugar and energy use. Retatrutide has been studied in receptor assays, animal models and phase 2 and phase 3 human trials. It remains investigational and this research material is not an approved medicine.

MaterialInvestigational peptide receptor agonist

Main research areaGLP-1, GIP and glucagon signalling

Evidence availableLaboratory, animal and phase 2/3 human research

Catalogue categoryMetabolic Signaling Research

How It Works

Normal target and function. GLP-1 and GIP are natural signals released after food. GLP-1 signalling can slow how quickly food leaves the stomach and reduce hunger signals. GLP-1 and GIP also help the pancreas release insulin when glucose is present. Glucagon normally releases stored fuel to maintain glucose supply. Retatrutide activates all three systems, so trials measure appetite-related, body-weight and blood-glucose changes.

GLP-1 and GIP are natural signals released after food, while glucagon helps regulate the supply of glucose and stored energy. Retatrutide research asks how one molecule can activate all three receptors and how the balance of those signals affects metabolic measurements. Structural studies examine how it fits each receptor. Clinical trials study an investigational drug product under controlled conditions; their findings do not establish equivalence for this 5 mg laboratory listing.

Three receptors

The molecule is designed to activate GLP-1, GIP and glucagon receptors.

Signal balance

Researchers compare the strength and pattern of the three receptor responses.

Metabolic models

Studies measure how receptor signals relate to glucose and energy regulation.

Investigational status

Phase 2 and phase 3 research exists, but retatrutide is not an approved medicine.

Laboratory and Animal Research

Laboratory studies show binding and signalling at the GLP-1, GIP and glucagon receptors. Animal metabolic studies reported changes that supported clinical development. These models helped explain the triple-receptor design but cannot establish a human outcome by themselves.

Measurements used in these studies

Activation of each of the three target receptors
Differences in signal strength and timing between receptors
Glucose and energy-related measurements in controlled animal studies
Body-weight, HbA1c and safety outcomes in investigational human trials

Human Research

What human studies have reported

Controlled phase 2 obesity and diabetes trials, followed by a 2026 phase 3 diabetes trial, reported reductions in body weight and blood-glucose measures for an investigational retatrutide drug product. Retatrutide remains under clinical development and is not an approved medicine.

Effects researchers measured

Body weight and waist-related measurements in controlled obesity research
HbA1c and other blood-glucose measurements in type 2 diabetes trials
Phase 3 evidence now exists for the studied investigational drug product, but long-term and broader outcomes remain under study

Adverse effects reported

Nausea, diarrhoea, vomiting and constipation were the most frequent events in the phase 2 obesity trial.
Gastrointestinal events were usually mild to moderate and were also the most frequent events in the phase 3 diabetes trial.
A temporary increase in heart rate was observed in the phase 2 obesity trial.

Product boundary. Trial findings apply to the manufactured investigational drug, participant groups and monitored protocols that were studied. The “5 mg” catalogue amount does not show that this vial is equivalent to any trial product.

Evidence type	What was studied	How much evidence	What this means
Laboratory research	Receptor and structural studies	Mechanistic	Studies show how retatrutide interacts with GLP-1, GIP and glucagon receptors.
Animal research	Controlled metabolic models	Preclinical	Animal studies informed development but do not by themselves predict human outcomes.
Human research	Phase 2 and phase 3 trials	Meaningful investigational evidence	Trials reported lower body-weight and blood-glucose measures for an investigational drug product. This does not establish approval or equivalence for this listing.

Limits of the Evidence

Retatrutide remains under clinical development and is not an approved medicine.
Trial results apply to the specific investigational formulation and controlled protocol studied.
Long-term effects and the full benefit-risk profile remain under study.